Literature DB >> 15148576

Interferon update.

S Pyrhönen1.   

Abstract

Mesh:

Substances:

Year:  2004        PMID: 15148576     DOI: 10.1007/s00120-004-0604-8

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  3 in total

1.  Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.

Authors:  M Kankuri; T T Pelliniemi; S Pyrhönen; V Nikkanen; H Helenius; E Salminen
Journal:  Cancer       Date:  2001-08-15       Impact factor: 6.860

2.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

Authors:  S Pyrhönen; E Salminen; M Ruutu; T Lehtonen; M Nurmi; T Tammela; H Juusela; E Rintala; P Hietanen; P L Kellokumpu-Lehtinen
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.

Authors: 
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.